Decision Resources
Decision Resources details recent developments
Published in Health Business Week, January 12th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Decision Resources.
Report 1: Decision Resources has found that the launch of novel, premium-priced drugs and the progression of Wyeth's Mylotarg (gemtuzumab ozogamicin) to a first-line therapy will more than double the market to treat acute myeloid leukemia (AML) by 2015.
The new Pharmacor report "Acute Myeloid Leukemia" finds increased use of Mylotarg and the launches of Genzyme/Bioenvision's Clolar/Evoltra (clofarabine), Vion's Cloretazine (VNP-40101M), and SuperGen/MGI Pharma's...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2007-01-12)
More Articles from Health Business Week
- Accreditation
ACM-Pivotal Europe awarded key accreditation - Adolescent Health
Pennsylvania Governor Rendell announces results of state's first adolescent health survey - Alzheimer Disease
Memory Pharmaceuticals reports U.S. FDA release of clinical hold on Alzheimer drug MEM 3454 - Alzheimer Disease
Nymox protein biomarker for Alzheimer is years ahead of competition - Anemia
Abt analysis suggests lower drug cost for Procrit in outpatient setting - Anemia
Affymax presents results from phase II trial of Hematide in anemic cancer patients - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
